Carence en fer, anémie et anémie ferriprive chez les donneurs de sang à Kinshasa, République Démocratique du Congo

Introduction: En République Démocratique du Congo (RDC), plus d'un million de don de sang ont été réalisés entre 2007 et 2011. Cependant, aucun bilan portant sur la carence en fer et l'anémie ferriprive, conséquence d'un don de sang chez les donneurs de sang (DS), n'est disponible dans ce pays. L'objectif de cette étude était d'estimer la prévalence de la carence en fer, de l'anémie et de l'anémie ferriprive chezles DS au Centre National de Transfusion Sanguine (CNTS) à Kinshasa en RDC. Méthodes: Entre Décembre 2012 et Août 2013, une étude transversale a été menée au CNTS où des DS éligibles au don de sang ont été inclus. Les informations socio démographiques et des prélèvements sanguins ont été collectés de manière simultanée au don de sang. La ferritine sérique a été dosée pour évaluer la carence en fer en utilisant la technique ELISA. L'hémogramme a été réalisé en vue d'évaluer et mettre au point l'anémie. Résultats: Au total 386 DS ont été inclus dans cette étude. La prévalence de la carence en fer et de l'anémie ferriprive étaient respectivement de 63,2% (244/386) et 25,9% (100/386) des DS. Une anémie a été trouvée chez 36.5% (141/386) au moment du don de sang. Conclusion: La carence en fer, l'anémie et l'anémie ferriprive demeurent très fréquentes chez les DS à Kinshasa. Ces résultats suggèrent la révision des tests biologiques utilisés dans le recrutement des DS au CNTS. Par ailleurs le dosage de la ferritine s'impose en routine chez les DS régPan African Medical Journal 2016; 2

A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS

The first experimental immunization of humans against the AIDS retrovirus, HIV-1, was started in a series of HIV seronegative, healthy volunteers in November 19861. For the primary vaccination recombinant vaccinia virus (V25)2 expressing the complete gp160 env protein3 of the HTLV-IIIB strain4,5 of HIV-1 was introduced by scarification. This elicited a weak primary response which we subseqently attempted to enhance by additional immunizations (boosting), using four different immunization protocols. We report here that intravenous injection of paraformaldehyde-fixed autologous cells infected in vitro with V25 (individual D.Z.) gave the best results. This individual received second and third boosts of intramuscular gp160 derived from an HTLV-IIIB clone using the hybrid vaccinia virus/bacteriophage T7 expression system6. An anamnestic humoral and cellular immune reaction was achieved for over one year after the original vaccination, with high levels of antibodies to the viral envelope, and neutralizing antibodies against divergent HIV-1 strains such as HTLV-III B4,5,7 and HTLV-IIIRF (also called HTLV-III HAT)3,5 after the first boost. In addition, group-specific cell-mediated immunity and cell-mediated cytotoxicity against infected T4 cells were obtained after the primary vaccine and enhanced by the boosts. Finally, skin tests showed both immediate and delayed hypersensitivity to gp160 in vivo. Although this protocol is not practical for a large scale vaccine trial, our results show for the first time that an immune state against HIV can be obtained in man. © 1988 Nature Publishing Group.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

One-year follow-up of vaccine therapy in hiv-infected immune-deficient individuals: A new strategy

Immunization of AIDS/ARC patients with autologous cells expressing HIV antigens, although providing clinical and biological benefits, fails to restore cellular immunity. The latter result is due partly to the antiproliferative effect of HIV-1 on activated T-cells (immune suppression), which leads to blockade of specific immune reactions. To overcome immune suppression, a new vaccine strategy was designed consisting of an immunization against HIV-1 combined with components of the T-cell-suppressive (antiproliferative) network. This new vaccine treatment proved to be innocuous in mice, monkeys, and two non-HIV-infected humans. A Phase I clinical trial was performed in six patients previously under cellular immunotherapy and still presenting a cellular immune defect. Preliminary results confirmed, after a 1-year follow-up of the patients, the safety of the new vaccine, which also partially restored the cellular immune response, including anti-HIV HLA-restricted cell-mediated cytotoxicity, delayed hypersensitivity to recall antigens, and proliferation of T-cells specifically activated by recall antigens. © 1992 Raven Press, New York.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS

The first experimental immunization of humans against the AIDS retrovirus, HIV-1, was started in a series of HIV seronegative, healthy volunteers in November 19861. For the primary vaccination recombinant vaccinia virus (V25)2 expressing the complete gp160 env protein3 of the HTLV-IIIB strain4,5 of HIV-1 was introduced by scarification. This elicited a weak primary response which we subseqently attempted to enhance by additional immunizations (boosting), using four different immunization protocols. We report here that intravenous injection of paraformaldehyde-fixed autologous cells infected in vitro with V25 (individual D.Z.) gave the best results. This individual received second and third boosts of intramuscular gp160 derived from an HTLV-IIIB clone using the hybrid vaccinia virus/bacteriophage T7 expression system6. An anamnestic humoral and cellular immune reaction was achieved for over one year after the original vaccination, with high levels of antibodies to the viral envelope, and neutralizing antibodies against divergent HIV-1 strains such as HTLV-III B4,5,7 and HTLV-IIIRF (also called HTLV-III HAT)3,5 after the first boost. In addition, group-specific cell-mediated immunity and cell-mediated cytotoxicity against infected T4 cells were obtained after the primary vaccine and enhanced by the boosts. Finally, skin tests showed both immediate and delayed hypersensitivity to gp160 in vivo. Although this protocol is not practical for a large scale vaccine trial, our results show for the first time that an immune state against HIV can be obtained in man. © 1988 Nature Publishing Group.SCOPUS: ar.jinfo:eu-repo/semantics/publishe